The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network ( EMN )
Year: 2026
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: We performed a comprehensive review with meta- and network meta-analyzes of maintenance-therapy studies. Lenalidomide, proteasome inhibitors, and CD38 antibodies improved progression-free survival (PFS). However, overall survival (OS) benefit appeared only with lenalidomide in transplant-eligible (TE) patients, while CD38-directed therapy showed a trend toward improved OS not seen with proteasome inhibitors. The network meta-analysis ranked regimens against observation: daratumumab-lenalidomide (DR) yielded the greatest PFS benefit, followed by carfilzomib-lenalidomide-dexamethasone (KRd), KR in TE, and DRd in transplant-ineligible patients. Significant OS prolongation in TE patients occurred with KR, DR, and lenalidomide alone.
Source: American Journal of Hematology
DOI: 10.1002/ajh.70397
Authors: Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld
Institutions: Wilhelminen Hospital, National and Kapodistrian University of Athens, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, University of Freiburg, Oslo University Hospital, Universitätsklinikum Würzburg, Newcastle University, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, Instituto de Investigación Biomédica de Salamanca, Istinye University, Kantonsspital St. Gallen, Universidad de Cantabria, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, University College London Hospitals NHS Foundation Trust, Centre Hospitalier Universitaire de Nantes, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, University of Bari Aldo Moro, Erasmus MC Cancer Institute, Korea University, NTT (Italy)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,450
OpenAlex ID: W7165129090